Literature DB >> 6130101

Pituitary adenomas that caused Cushing's disease or Nelson's syndrome are not responsive to ovine corticotropin-releasing factor in vitro.

T Shibasaki, M Nakahara, K Shizume, Y Kiyosawa, T Suda, H Demura, A Kuwayama, N Kageyama, R Benoit, N Ling.   

Abstract

The response of pituitary adenomas obtained surgically from patients with Cushing's disease of Nelson's syndrome to synthetic ovine corticotropin-releasing factor (CRF), vasopressins, somatostatin-28, dexamethasone, 3-isobutylmethylxanthine or high [K+] was examined in vitro by measuring the amount of pro-opiomelanocortin (POMC)-derived peptides secreted into the culture medium. CRF did not stimulate the secretion of adrenocorticotropin-, beta-endorphin-, or gamma 3-melanotropin-like peptides from the pituitary adenomas at concentrations ranging from 1 x 10(-13) M to 1 x 10(-7) M whereas vasopressins, 3-isobutyrl-methylxanthine and high [K+] increased, while somatostatin-28 and dexamethasone suppressed, the secretion of these POMC-derived peptides. These findings suggest that either the pituitary ACTH-producing tumors have lost their receptors to CRF or their post-receptor mechanism to CRF is not functional.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6130101     DOI: 10.1210/jcem-56-2-414

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  2 in total

1.  Long-term culture of human corticotropin-secreting adenomas on extracellular matrix and evaluation of serum-free conditions. Secretory aspects.

Authors:  M Westphal; P Jaquet; C B Wilson
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

2.  Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas.

Authors:  Maria Francesca Cassarino; Antonella Sesta; Luca Pagliardini; Marco Losa; Giovanni Lasio; Francesco Cavagnini; Francesca Pecori Giraldi
Journal:  Endocrine       Date:  2016-05-24       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.